Form 4: BIO-TECHNE Exec's Equity Changes & Future Vesting
Insider Transaction Report
A recent SEC Form 4 filing details Matthew McManus's acquisition and disposition of BIO-TECHNE common stock, alongside significant new equity grants and future vesting schedules.
Summary
- Matthew McManus, President Diag & Spatial Bio at BIO-TECHNE Corp (TECH), reported equity transactions on August 15, 2025.
- Acquired 2,637 shares of common stock at a price of $0, likely from the vesting of restricted stock units.
- Disposed of 880 shares of common stock at $53.6 per share, likely to cover tax obligations related to the acquisition.
- Beneficial direct ownership of common stock is 4,735 shares following these reported transactions.
- Received new grants on August 15, 2025, including 19,243 Performance Restricted Stock Units, 9,622 Restricted Stock Units, and options to purchase 24,614 shares of common stock, all acquired at a $0 price.
- Holds significant unvested equity, including 37,956 Performance Restricted Stock Units, 14,858 Restricted Stock Units, and options to purchase 49,887 shares of common stock, with various future vesting dates.
Sentiment
Score: 7
Explanation: The filing indicates a routine set of transactions for an executive, including the vesting of existing equity and the grant of new long-term incentives. The net effect on direct ownership is a decrease due to tax withholding, but the overall picture shows continued alignment with shareholder interests through significant unvested equity.
Positives
- Significant new equity grants (19,243 Performance RSUs, 9,622 RSUs, 24,614 stock options) demonstrate continued long-term incentive alignment with company performance and executive retention.
- The acquisition of 2,637 shares at $0 indicates the successful vesting of previously granted equity, converting contingent rights into common stock.
- Substantial unvested equity holdings (over 100,000 shares/units across various types) indicate strong commitment and future potential for the executive, aligning their interests with long-term shareholder value.
Negatives
- Disposition of 880 shares at $53.6, likely for tax purposes, resulted in a reduction of direct common stock holdings.
Future Outlook
The filing does not contain forward-looking statements regarding the company's financial performance or strategic outlook, focusing solely on executive equity transactions and vesting schedules.
Industry Context
This filing is a routine disclosure of executive equity transactions, common across all publicly traded companies, and does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology and diagnostics sector.
Stakeholder Impact
- Shareholders: The executive's continued accumulation of unvested equity aligns their interests with long-term shareholder value creation. The disposition for tax purposes is a standard practice and not indicative of a lack of confidence.
- Employees: No direct impact mentioned.
- Customers/Suppliers/Creditors: No direct impact mentioned.
Next Steps
- Future vesting of Performance Restricted Stock Units on 8/15/2026, 8/15/2027, and 8/15/2028, contingent on performance goals.
- Future vesting of Restricted Stock Units on 2/1/2025, 2/1/2026, 2/1/2027, 8/15/2025, 8/15/2026, 8/15/2027, and 8/15/2028.
- Future vesting of Stock Options on 2/1/2025, 2/1/2026, 2/1/2027, 2/1/2028, 8/15/2025, 8/15/2026, 8/15/2027, and 8/15/2028.
Key Dates
| Date | Description |
|---|---|
| 2025-02-01 | Vesting date for 4,620 Restricted Stock Units and 3,976 Stock Options. |
| 2025-08-15 | Transaction date for common stock acquisition and disposition; vesting date for 2,637 Restricted Stock Units and 5,330 Stock Options; grant date for new Performance Restricted Stock Units, Restricted Stock Units, and Stock Options. |
| 2025-08-19 | Filing date of the Form 4. |
| 2026-02-01 | Vesting date for 4,621 Restricted Stock Units and 3,975 Stock Options. |
| 2026-08-15 | Vesting date for 2,637 Restricted Stock Units; potential vesting date for 2,888 Performance Restricted Stock Units if performance goals are achieved; vesting date for 5,330 Stock Options and 8,205 Stock Options; vesting date for 3,207 Restricted Stock Units. |
| 2027-02-01 | Vesting date for 4,620 Restricted Stock Units and 3,976 Stock Options. |
| 2027-08-15 | Vesting date for 2,638 Restricted Stock Units; potential vesting date for 15,825 Performance Restricted Stock Units if performance goals are achieved; vesting date for 5,330 Stock Options and 8,205 Stock Options; vesting date for 3,207 Restricted Stock Units. |
| 2028-02-01 | Vesting date for 3,975 Stock Options. |
| 2028-08-15 | Vesting date for 5,330 Stock Options and 8,204 Stock Options; vesting date for 3,208 Restricted Stock Units; potential vesting date for 19,243 Performance Restricted Stock Units if performance goals are achieved. |
| 2031-02-01 | Expiration date for Performance Stock Options and Stock Options with $68.54 exercise price. |
| 2034-08-15 | Expiration date for Stock Options with $74.91 exercise price. |
| 2035-08-15 | Expiration date for Stock Options with $53.6 exercise price. |
Recommendation
holdThe Form 4 filing details routine equity compensation transactions for a key executive, including the vesting of restricted stock units and the grant of new performance-based awards. The disposition of shares was likely for tax withholding, a common practice. These transactions do not indicate a material change in the company's fundamentals or the executive's long-term commitment, thus a 'hold' recommendation is appropriate as the filing itself does not provide new information to warrant a change in investment thesis.
Keywords
BIO-TECHNE, TECH, SEC Form 4, Insider Trading, Equity Compensation, Restricted Stock Units, Stock Options, Executive Compensation, Matthew McManus, Biotechnology, Diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.